Next-generation cancer diagnostics
Cancer changes glycans.
We detect the differences.
Sequencing this major class of biomarkers to detect cancer across multiple glycoproteins. From a blood sample.
01
GlycoSeq™
Decoding the glycome.
01 The problem
DNA, RNA, & protein sequencing transformed diagnostics.
We're tackling the last major class of unsequenceable biomolecules–Glycans
Glycan sequencing makes the diagnosis
We’re adding a serum test to the non-invasive risk factors in our models. GlycoSeq™ measures glycan patterns across proteins, adding a powerful new molecular signal to our screeners.
02 Our approach
Our platform: GlycoSeq™
GlycoSeq reads glycan patterns across multiple proteins to build richer, multi-marker cancer signatures.
01CaptureIsolate the target protein
02SequenceDetect glycosylation patterns
03InterpretConvert glycosylation patterns to clinical signals
03 Partners
Investors &
strategic partners.
Partner
Backer
04 The team
Bridging science & business
CEOArthur Costa
BS Chemical Biology, UChicago ’27Chemistry and biology research background, trained by Nobel Laureates Jack Szostak and Jennifer Doudna.
COONora Levy
BA/MA Economics, UChicago ’27Operations, fundraising, and long-term project management background.
CTOMichael Bolgov
BS Molecular Engineering, UChicago ’27Biomolecular engineering research and quantitative product strategy background.
05 Join Oxum
Help build a more
specific future.
Join a focused team building a new diagnostic platform.
View opportunitiesStaff Scientist
Lead experiments and translate our roadmap into lab practice.
Lab Technician
Run experiments alongside senior scientists.
Oxum Interns
Hands-on research for early undergraduates.
06 Contact
Let's move diagnostics
forward.
Research, investment, careers, or collaboration.
contact@oxumglyco.com